Cargando…

Tumor targeting using liposomal antineoplastic drugs

During the last years, liposomes (microparticulate phospholipid vesicles) have been used with growing success as pharmaceutical carriers for antineoplastic drugs. Fields of application include lipid-based formulations to enhance the solubility of poorly soluble antitumor drugs, the use of pegylated...

Descripción completa

Detalles Bibliográficos
Autores principales: Huwyler, Jörg, Drewe, Jürgen, Krähenbühl, Stephan
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526358/
https://www.ncbi.nlm.nih.gov/pubmed/18488413
_version_ 1782158738475450368
author Huwyler, Jörg
Drewe, Jürgen
Krähenbühl, Stephan
author_facet Huwyler, Jörg
Drewe, Jürgen
Krähenbühl, Stephan
author_sort Huwyler, Jörg
collection PubMed
description During the last years, liposomes (microparticulate phospholipid vesicles) have been used with growing success as pharmaceutical carriers for antineoplastic drugs. Fields of application include lipid-based formulations to enhance the solubility of poorly soluble antitumor drugs, the use of pegylated liposomes for passive targeting of solid tumors as well as vector-conjugated liposomal carriers for active targeting of tumor tissue. Such formulation and drug targeting strategies enhance the effectiveness of anticancer chemotherapy and reduce at the same time the risk of toxic side-effects. The present article reviews the principles of different liposomal technologies and discusses current trends in this field of research.
format Text
id pubmed-2526358
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-25263582008-09-04 Tumor targeting using liposomal antineoplastic drugs Huwyler, Jörg Drewe, Jürgen Krähenbühl, Stephan Int J Nanomedicine Review During the last years, liposomes (microparticulate phospholipid vesicles) have been used with growing success as pharmaceutical carriers for antineoplastic drugs. Fields of application include lipid-based formulations to enhance the solubility of poorly soluble antitumor drugs, the use of pegylated liposomes for passive targeting of solid tumors as well as vector-conjugated liposomal carriers for active targeting of tumor tissue. Such formulation and drug targeting strategies enhance the effectiveness of anticancer chemotherapy and reduce at the same time the risk of toxic side-effects. The present article reviews the principles of different liposomal technologies and discusses current trends in this field of research. Dove Medical Press 2008-03 2008-03 /pmc/articles/PMC2526358/ /pubmed/18488413 Text en © 2008 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Huwyler, Jörg
Drewe, Jürgen
Krähenbühl, Stephan
Tumor targeting using liposomal antineoplastic drugs
title Tumor targeting using liposomal antineoplastic drugs
title_full Tumor targeting using liposomal antineoplastic drugs
title_fullStr Tumor targeting using liposomal antineoplastic drugs
title_full_unstemmed Tumor targeting using liposomal antineoplastic drugs
title_short Tumor targeting using liposomal antineoplastic drugs
title_sort tumor targeting using liposomal antineoplastic drugs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526358/
https://www.ncbi.nlm.nih.gov/pubmed/18488413
work_keys_str_mv AT huwylerjorg tumortargetingusingliposomalantineoplasticdrugs
AT drewejurgen tumortargetingusingliposomalantineoplasticdrugs
AT krahenbuhlstephan tumortargetingusingliposomalantineoplasticdrugs